EMA Authorised: Slenyto (melatonin) — RAD Neurim Pharmaceuticals EEC SARL

View source ↗

Summary

Slenyto (melatonin) has been authorized for sleep initiation and maintenance disorders and autistic disorder in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autistic Disorder
• Sleep Initiation and Maintenance Disorders

Drugs mentioned

• Slenyto (melatonin)

Snippet

Status: Authorised. Therapeutic area: Sleep Initiation and Maintenance Disorders;Autistic Disorder. MAH: RAD Neurim Pharmaceuticals EEC SARL. Decision date: 09/06/2026